3.5 LITERATURE CITED 
1 . Bernards R., Suppression of MHC gene expression in cancer cells. Trends Genet. 3:298-301, 
1987. 
2. Tanaka K., Yoshioka T., Bieberich C., and Jay G., Role of the major histocompatibility 
complex class I antigens in tumor growth and metastasis. Annu. Rev. Immunol. 6:359, 1988. 
3. Townsend A., Rothbard J., Gotch F., Bahadur G., Wraith D., and McMichael A., The 
epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined 
with short synthetic peptides. Cell 44:959-968, 1986. 
4. Townsend A., Ohlen C., Bastin J., Ljunggren H-G., Foster L., and Karre K., Association of 
class I major histocompatibility heavy and light chains induced by viral peptides. Nature 
340:443-448, 1989. 
5. Baldwin R., Price M., and Robins R., Inhibition of hepatoma-immune lymph-node cell 
cytotoxicity by tumor-bearer serum and solubilized hepatoma antigen. Int J Cancer 1 1:527- 
535, 1973. 
6. Fujimoto S., Greene M., Sehon A., Regulation of the immune response to tumor antigens. I. 
Immunosuppressor cells in tumor-bearing hosts. II. The nature of immunosuppressor cells in 
tumor-bearing hosts. J. Immunol. 116:791-806, 1976. 
7. Hoon D., Foshag L., Nizze A., Bohman R., and Morton D., Suppressor cell activity in a 
randomized trial of patients receiving active specific immunotherapy with melanoma cell 
vaccine and low dosages of cyclophosphamide. Cancer Res. 50:5358-5364, 1990. 
8. Ettinghausen S., Moore J., White D., Platanias L., Young N., and Rosenberg S., 
Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant 
interleukin-2 in cancer patients. Blood 69:1654-1660, 1987. 
9. Rosenberg S., Mule J., Spiess P., Reichert C., and Schwarz S., Regression of established 
pulmonary metastases and subcutaneous tumors mediated by the systemic administration of 
high dose recombinant Interleukin 2. J. Exp. Med. 161:1 169, 1985. 
10. Rosenberg S., Lotze M., Yang J., Aebersold P., Linehan W., Seipp C., White D., 
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. 
Ann. Surg. 210:474, 1989. 
1 1. Erard F., Corthesy P., Nabholz M., Lowenthal J., Zaech P., Plaetnick G., and Macdonald 
H., Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin- 
stimulated cytolytic T lymphocyte precursors. J. Immunol. 134:1644, 1985. 
Recombinant DNA Research, Volume 17 
[633] 
